Glycodelin reduces breast cancer xenograft growth in vivo

Int J Cancer. 2008 Nov 15;123(10):2279-84. doi: 10.1002/ijc.23773.

Abstract

Malignant growth is characterized by loss of cell differentiation, uncontrolled proliferation and resistance to apoptosis. Many tumor suppressor genes that protect cells against malignant transformation regulate cell differentiation. Here, we show for the first time that glycodelin, a differentiation-related protein, reduces breast cancer tumor growth in vivo. We found that glycodelin cDNA-transfected MCF-7 breast cancer cells showed a differentiated phenotype and produced smaller tumors in mouse mammary fat pads compared with control-transfected cells. Glycodelin-induced differentiation was associated with reduced expression of oncogenes and increased expression of tumor suppressor genes. Our results suggest that glycodelin acts as a tumor suppressor in breast cancer. This may explain its reported association with a more favorable prognosis in some cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms / genetics
  • Breast Neoplasms / pathology*
  • Cell Differentiation / drug effects
  • Cell Division / drug effects*
  • Gene Expression Profiling
  • Glycodelin
  • Glycoproteins / pharmacology*
  • Humans
  • Mice
  • Neoplasm Transplantation
  • Oligonucleotide Array Sequence Analysis
  • Pregnancy Proteins / pharmacology*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Glycodelin
  • Glycoproteins
  • PAEP protein, human
  • Pregnancy Proteins